Loading...
Loading...
Browse all stories on DeepNewz
VisitMarket share impact on Alcon due to Systane recall by end of 2025?
Alcon loses market share • 25%
Alcon gains market share • 25%
No significant change • 25%
Other outcome • 25%
Market share analysis reports from industry analysts
Alcon Recalls One Lot of Systane Eye Drops Nationwide Due to Fungal Contamination, FDA Warns of Vision-Threatening Risks
Dec 26, 2024, 07:01 PM
Systane brand eye drops have been recalled nationwide due to possible fungal contamination, according to an announcement from the Food and Drug Administration (FDA). The recall affects one lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, after a consumer reported finding a foreign material in a sealed vial. Upon investigation, the Texas-based manufacturer, Alcon, confirmed that the material was fungal in nature. The FDA has warned that this contamination could lead to eye infections that may threaten vision, particularly in immunocompromised individuals. The recalled eye drops are commonly used for temporary relief of burning and irritation associated with dry eye symptoms and are sold at retailers including Publix and Amazon. Consumers are advised to check their medicine cabinets for the affected product.
View original story
No further action • 25%
Fine imposed • 25%
Mandatory product reformulation • 25%
Temporary production halt • 25%
No significant change • 25%
Switch to alternative brands • 25%
Decreased trust in Alcon • 25%
Increased demand for safer packaging • 25%
Product reformulation • 25%
Increased quality checks • 25%
Discontinue product • 25%
No significant changes • 25%
Minor compliance issues • 25%
Major compliance issues • 25%
No issues found • 25%
Recall expanded • 25%
Decreases slightly • 25%
Decreases significantly • 25%
Increases • 25%
Remains stable • 25%
CVS • 25%
Other • 25%
Target • 25%
Walgreens • 25%
Other regions • 25%
North America • 25%
Europe • 25%
Asia • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
No significant change (+/- 10%) • 25%
Other outcome • 25%